Results 181 to 190 of about 12,789,497 (387)

Disease Progression

Definitions, 2020

semanticscholar   +1 more source

Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models

Molecular Oncology, EarlyView.
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon, Moa Stenudd, Margherita Zamboni, Kanar Alkass, Carl‐Johan Eriksson, Lars Pedersen, Alrik Schörling, Anna Thoss, Anders Bergh, Pernilla Wikström, Hans‐Olov Adami, Henrik Toft Sørensen, Henrik Druid, Jonas Frisén   +13 more
wiley   +1 more source

The correlation between clinical outcomes and genomic analysis with high risk factors for the progression of osteosarcoma

Molecular Oncology
Osteosarcoma (OS) is a rare but aggressive malignancy. Despite previous reports, molecular characterization of this disease is not well understood, and little is known regarding OS in Chinese patients.
Weifeng Liu, Huanqing Cheng, Zhen Huang, Yaping Li, Yanrui Zhang, Yongkun Yang, Tao Jin, Yang Sun, Zhiping Deng, Qing Zhang, Feng Lou, Shanbo Cao, Huina Wang, Xiaohui Niu   +13 more
doaj   +1 more source

Epigenomic Echoes—Decoding Genomic and Epigenetic Instability to Distinguish Lung Cancer Types and Predict Relapse

Epigenomes
Genomic and epigenomic instability are defining features of cancer, driving tumor progression, heterogeneity, and therapeutic resistance. Central to this process are epigenetic echoes, persistent and dynamic modifications in DNA methylation, histone ...
Alexandra A. Baumann, Zholdas Buribayev, Olaf Wolkenhauer, Amankeldi A. Salybekov, Markus Wolfien   +4 more
doaj   +1 more source

HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion [PDF]

, 1994
Alessandro Cozzi Lepri, Patrizio Pezzotti, Maria Dorrucci, A. N. Phillips, Giovanni Rezza   +4 more
openalex   +1 more source

Disease progression in systemic sclerosis [PDF]

Rheumatology, 2021
Leeuwen, N.M. van, Liem, S.I.E., Maurits, M.P., Ninaber, M., Marsan, N.A., Allaart, C.F., Huizinga, T.W.J., Knevel, R., Vries-Bouwstra, J.K. de   +8 more
openaire   +4 more sources

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

Molecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková, Marie Ehrlichová, Alžběta Spálenková, Ivona Krus, Simona Šůsová, Viktor Hlaváč, Vlasta Němcová, Renata Koževnikovová, Markéta Trnková, David Vrána, Jiří Gatěk, Kateřina Kopečková, Marcela Mrhalová, Soňa Měšťáková, Pavel Souček   +14 more
wiley   +1 more source

Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia [PDF]

, 1990
Catherine M. Verfaillie, NE Kay, W Miller, Philip B. McGlave   +3 more
openalex   +1 more source

Quality of life evidence for patients with Alzheimer’s disease: use of existing quality of life evidence from the ADENA trials to estimate the utility impact of Exelon® [PDF]

This paper utilises the Mini-Mental State Examination (MMSE) score of patients with Alzheimer’s disease to establish a relationship between disease progression and quality of life measures, and the author also compares his results to findings from the ...
Brazier, J
core   +1 more source

Association of high‐dose radioactive iodine therapy with PPM1D‐mutated clonal hematopoiesis in older individuals

Molecular Oncology, EarlyView.
In thyroid cancer patients, high‐dose (≥7.4 GBq) radioactive iodine therapy (RAIT) was associated with a higher prevalence of clonal hematopoiesis (variant allele frequency >2%) in individuals aged ≥50 years (OR = 2.44). In silico analyses showed that truncating PPM1D mutations conferred a selective advantage under these conditions.
Jaeryuk Kim, Sungwoo Bae, Jaeyong Choi, Sun‐Wha Im, Bukyoung Cha, Gyeongseo Jung, Sun Wook Cho, Eul‐Ju Seo, Young Ah Lee, Jin Chul Paeng, Young Joo Park, Jong‐Il Kim   +11 more
wiley   +1 more source